

Tumor evolution and progression in multifocal and paired non-invasive/invasive urothelial carcinoma

Joshua I. Warrick^{1^}, Daniel H. Hovelson^{2^}, Anmol Amin¹, Chia-Jen Liu¹, Andi K. Cani¹, Andrew S. McDaniel¹, Venkata Yadati¹, Michael J. Quist^{1,7}, Alon Z. Weizer^{5,6}, J. Chad Brenner³, Felix Y. Feng^{4,5}, Catherine S. Grasso^{1,7}, Scott A. Tomlins^{1,5,6}

Supplementary Materials

Supplementary Figure Legend	Page 1
Supplementary Figure 1	Page 2
Supplementary Table 1	Page 3
Supplementary Table 2	Page 4
Supplementary Table 3	Page 5
Supplementary Table 4	Page 6

Figure S1: Macrodissection and sequencing of normal urothelium demonstrates lack of clonal founding mutations observed in multifocal tumors. Two areas of histologically normal urothelium (BL193A and BL193B) from Case 1 were macrodissected and subjected to targeted DNA based next generation sequencing (NGS) using a custom Ion Torrent Ampliseq panel targeting ~130 genes. This panel covers two shared clonal mutations present in all multifocal urothelial carcinoma (UC) tumor specimens identified herein (*HRAS* Q61L and *PIK3CA* H1047L). **A-E.** Blocks with normal urothelium (20x original magnification in **A**, 2x in **B**) were cut, and unstained slides were visualized under a microscope (**C**), urothelium was identified (**D**) and macrodissected with confirmation of enrichment for urothelium (**E**). Original magnification 2x in **C-E** The read level support for the *HRAS* and *PIK3CA* mutations present in all tumor specimens is indicated. **F-J.** As in **A-E**, except for a second area of histologically normal urothelium from a separate block (BL193B).





Table S1: DNA next generation sequencing statistics for urothelial carcinoma samples

Sample	Case	Type	Estimated Tumor content	DNA isolated	Sequencer	Panel	Number of mapped reads	Percent reads on target ¹	Average base coverage depth	Uniformity of base coverage	Target base coverage at 1x	Target base coverage at 20x	Target base coverage at 100x	Variant Calls
BL193	1	Benign Kidney	0%	1.83ug	PGM	CCP	6,162,548	99%	380	90%	99%	96%	87%	1080
BL191	1	pTa	70%	1.98ug	PGM	CCP	6,077,217	99%	377	92%	99%	96%	89%	1088
BL192	1	pTa	70%	1.07ug	PGM	CCP	4,483,190	99%	280	90%	99%	95%	82%	1136
BL194	1	pTa	70%	1.74ug	PGM	CCP	3,593,322	87%	179	89%	99%	94%	66%	1190
BL195	1	pTa	70%	1.58ug	PGM	CCP	5,731,464	99%	359	80%	98%	89%	76%	1079
BL196	1	pTa	70%	2.47ug	PGM	CCP	3,570,567	95%	212	89%	99%	95%	72%	1103
BL190	1	> pTa	70%	1.22ug	PGM	CCP	5,403,796	99%	342	91%	99%	96%	86%	1288
BL300	2	pTa	75%	1.16ug	Proton	CCP	33,863,024	99%	2102	89%	100%	98%	96%	1199
BL301	2	> pTa	40%	2.31ug	Proton	CCP	5,441,489	99%	328	87%	99%	94%	81%	1058
BL303mn	3	Benign Urothelium	0%	0.40ug	Proton	CCP	5,758,432	99%	346	86%	99%	95%	80%	1068
BL302	3	pTa	75%	3.35ug	Proton	CCP	7,505,325	99%	456	89%	99%	96%	88%	1158
BL303	3	> pTa	75%	1.35ug	Proton	CCP	6,595,021	99%	407	89%	99%	96%	87%	1096
BL305	4	pTa	80%	1.22ug	Proton	CCP	2,764,767	99%	163	82%	98%	88%	51%	807
BL306	4	> pTa	70%	3.88ug	Proton	CCP	3,708,029	99%	224	87%	99%	93%	70%	911

For each sample, the Case and whether the sample represented benign tissue, pTa or > pTa urothelial carcinoma is indicated. For Case 1, each sample was sequenced on a single Ion Torrent 318 chip on the PGM. For Cases 2-4, samples were multiplexed and sequenced on Ion PI chips on the Proton Sequencer.¹The comprehensive cancer panel (CCP) targets 1,688,650 bases in 409 genes.

Table S3. Targeted multiplexed PCR based RNA sequencing statistics for urothelial carcinoma samples

Sample	Case	Type	RNA isolated	Sequencer	Mapped Reads ¹	On Target	Amplicons with at least 10 reads
BL193A*	1	Benign Urothelium	0.66ug	PGM	495,367	1	105
BL193B*	1	Benign Urothelium	1.04ug	PGM	449,622	1	106
BL190	1	> pTa	2.30ug	PGM	174,513	1	104
BL191	1	pTa	3.86ug	PGM	527,004	1	105
BL192	1	pTa	1.40ug	PGM	329,882	1	106
BL194	1	pTa	1.86ug	PGM	549,018	1	107
BL195	1	pTa	2.21ug	PGM	479,483	1	107
BL196	1	pTa	2.01ug	PGM	410,994	1	108
BL300	2	pTa	3.58ug	PGM	349,796	1	104
BL301	2	> pTa	0.40ug	PGM	272,113	1	106
BL303mn	3	Benign Urothelium	2.48ug	PGM	289,895	1	109
BL302^	3	pTa	6.80ug	PGM	500,996	1	108
BL302b^	3	pTa	N/A	PGM	392,154	1	105
BL303	3	> pTa	1.30ug	PGM	278,034	1	105
BL305^	4	pTa	0.68ug	PGM	470,339	1	99
BL305b^	4	pTa	N/A	PGM	512,697	1	100
BL306	4	> pTa	0.10ug	PGM	60,836	1	91

For each sample, the Case and whether the sample represented benign urothelium, pTa or > pTa urothelial carcinoma is indicated. Samples were multiplexed and sequenced on Ion Torrent 318 chips. * indicates biological replicates from different blocks. ^ indicates technical replicates, with "b" samples subjected to 3 extra cycles during multiplexed PCR. ¹The custom RNA Ampliseq panel consisted of 111 amplicons targeting 8 housekeeping genes and 103 target genes.

